Kisspeptin
Hospital research only; repeated dosing desensitizes the hormone system.
The signal the brain uses to start releasing reproductive hormones. A research tool with promising hospital studies, mostly from one London group. Also called Kisspeptin-10, Kisspeptin-54 and Metastin.
What the evidence shows
Side effects and risks
Who should avoid it: Use outside a clinical study.
Athletes: Prohibited at all times (class S2). Added in 2024 as an example of testosterone-stimulating peptides, which are prohibited in males. USADA advisory on 2024 WADA list, 2023-10
How it works
- Where it acts
- Kisspeptin receptors on the brain cells that release GnRH.
- What it changes
- It triggers GnRH, which releases LH and FSH, the hormones that drive the ovaries and testes.
- What people notice
- In studies, an LH surge that can trigger egg maturation in IVF. Effects on desire have been studied in small groups.
How it has been given in studies
By infusion or injection in a hospital research unit. Kisspeptin-10 has a half-life of about 4 minutes and kisspeptin-54 about 28. There is no consumer dose.
Getting it in the United States
The legal route for Kisspeptin
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding, flagged by FDA
No approved product exists. Kisspeptin-10 was nominated for pharmacy compounding, but since 2023 the FDA lists it as a substance that may pose significant safety risks. Impurities and immune reactions are the stated concerns.
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Some men on testosterone therapy report better libido
Reported problems
- Inconsistent; wears off
Based on very few reports.
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
Leads the Imperial group behind most human kisspeptin trials. Senior author on the IVF egg maturation study and the low sexual desire studies, which the team says lay foundations for clinical use.
Waljit DhilloWebsiteRecommends
Money: NIHR research professorship funds his work
Photo source: endo2026.endocrine.org
Cautionary expert view
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
See all views 6
Leads the Imperial group behind most human kisspeptin trials. Senior author on the IVF egg maturation study and the low sexual desire studies, which the team says lay foundations for clinical use.
Waljit DhilloWebsiteRecommends
Money: NIHR research professorship funds his work
Photo source: endo2026.endocrine.org
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Devoted a full episode in 2024 to how these peptides are thought to work and how people use them. He presents possible benefits for healing, growth hormone, sleep and libido, and also says most of the data comes from animals, that black-market products may be contaminated, and that anyone with a tumor or cancer concern should avoid peptides that promote growth or new blood vessels.
Source: Huberman Lab episode, 1 Apr 2024
Andrew HubermanInstagramMixed view
Reported that a single infusion changed brain activity linked to arousal in 32 men and 32 women with low desire. Said longer studies, wider groups and simpler delivery routes are still needed.
Source: The Endocrinologist, Summer 2024
Edouard MillsWebsiteRecommends
Photo source: societyforendocrinology.wordpress.com
Put kisspeptin-10 on its list of compounding substances that may pose significant safety risks. Cited possible immune reactions, impurity problems and little or no safety data for the proposed routes.
Source: FDA compounding safety risks page, 2026-04, 2023-09
US Food and Drug AdministrationSourceWarns against
Co-led the first IVF trigger trial and led a study of a longer-acting kisspeptin receptor agonist in healthy women and women with polycystic ovary syndrome or hypothalamic amenorrhea. Concluded it has therapeutic potential.
Ali AbbaraWebsiteRecommends
Photo source: profiles.imperial.ac.uk
More contextCase reports, watch and read, emerging uses and chemistry
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Kisspeptin: the master regulator of reproduction?
Alexander Comninos and Waljit Dhillo
Researchers trace kisspeptin from a melanoma gene to the top of the reproductive hormone chain, and discuss possible therapies for fertility disorders.
Written by the clinical researchers who study it
Kisspeptin
Society for Endocrinology
Plain-language explainer on how kisspeptin drives puberty and fertility hormones, links to early or delayed puberty, and its study as a fertility treatment.
Easy starting point from an endocrinology society
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
FDA
FDA lists kisspeptin-10 as a compounding substance with immunogenicity and impurity concerns and little or no safety data for the proposed routes.
Regulator warning about compounded kisspeptin
When options run out
Uses people turn to when standard treatment has failed.
Egg maturation trigger in IVF
- Who
- Women having IVF, studied as an alternative to the standard hCG trigger because of concern about ovarian hyperstimulation.
- Evidence
- One Imperial trial of 53 women in 2014. Eggs matured at every dose and ten women had healthy babies. No head-to-head comparison in that study.
- Route
- Clinical trials at Imperial College London and Hammersmith Hospital
Low sexual desire in men and women
- Who
- Adults distressed by low desire. Options are few, especially for men, who have no licensed drug.
- Evidence
- Two small crossover trials of 32 people each using one hospital infusion and brain scans. No long-term or at-home treatment data.
- Route
- Research trials only
Source: The Endocrinologist, Summer 2024
Hypothalamic amenorrhea and polycystic ovary syndrome
- Who
- Women whose periods have stopped or who do not ovulate, where restoring natural hormone pulses is the aim.
- Evidence
- Hormone-response study with six women in each group using a longer-acting agonist. In women with hypothalamic amenorrhea the hormone surge came earlier than in healthy women. Preliminary: no ovulation or pregnancy outcomes.
- Route
- Research trials only
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Kisspeptin-10 shown.
Questions people ask
Does kisspeptin raise testosterone?
A single dose raises the signal hormone LH for a few hours. Repeated or continuous dosing desensitizes the hormone system it is meant to stimulate.
Does kisspeptin increase libido?
In a lab study of 32 men, an infusion increased brain and penile responses to sexual images, but it measured no real-world outcomes.
Is kisspeptin used in IVF?
In a trial of 62 women at high risk of ovarian overstimulation, mature eggs were collected from 98%, but it was not compared with the standard trigger.
Is kisspeptin safe?
FDA says safety data for kisspeptin-10 are lacking and has put it on its safety-risk list for compounding. In the UK it is given only in hospital research studies.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Abbara et al. 2017: kisspeptin-54 as an IVF trigger
- Mills et al. 2023: kisspeptin in men with low desire
- 2025 review of kisspeptin therapeutics
Structure: PubChem